Jianyang Liu, Helena Idborg, Marina Korotkova, Kristina Lend, Ronald van Vollenhoven, Jon Lampa, Anna Rudin, Dan Nordström, Bjorn Gudbjornsson, Gerdur Gröndal, Till Uhlig, Kim Hørslev-Petersen, Merete Lund Hetland, Mikkel Østergaard, Michael Nurmohamed, Per-Johan Jakobsson
BACKGROUND: Disease-modifying antirheumatic drugs (DMARDs) are widely used for treating rheumatoid arthritis (RA). However, there are no established biomarkers to predict a patient's response to these therapies. Prostanoids, encompassing prostaglandins, prostacyclins, and thromboxanes, are potent lipid mediators implicated in RA progression. Nevertheless, the influence of DMARDs on prostanoid biosynthesis in RA patients remains poorly understood. This study aims to assess the impact of various DMARDs on urinary prostanoids levels and to explore whether urinary prostanoid profiles correlate with disease activity or response to therapy...
March 5, 2024: Arthritis Research & Therapy